To the editor:

We read with interest the letter from Vischini *et al.* about the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the peritoneal effluent of a peritoneal dialysis (PD) patient.[@bib1] Coronavirus transmission occurs primarily via respiratory droplets, and it has been found inconsistently in body secretions and excretions.[@bib2] SARS-CoV-2 virion is 60--140 nanometers and could theoretically enter the peritoneal cavity via hematogenous diffusion or through the PD catheter after touch contamination.

This observation of Vischini *et al.* if confirmed, is important for daily clinical care of PD patients and handling of effluents. However, they found positive polymerase chain reaction tests in PD effluents in their patient 1 month after the first symptoms, calling into question whether the virus itself was present or whether it was just noncontagious RNA fragments. In our experience with serial PD effluent samplings from 3 PD patients with mild to moderate active coronavirus disease 2019 (COVID-19), we found results discordant with those of Vischini *et al.* We used quantitative reverse transcription polymerase chain reaction analysis based on the highly specific *RdRp* gene and *E* gene, in 2 independent laboratories. Although nasopharyngeal swabs obtained at admission showed high viral load in all 3 patients (cycle threshold value \<30), decreasing during hospitalization, none of the 11 PD effluent samplings at days 0--3--4--7 taken after a 12-hour dwell time tested positive, even after dialysate centrifugation. A blood sample was positive in only one patient (A. Candellier, A. Scohy, N. Gillet, *et al.*, submitted for publication, 2020). Our data are also in line with the absence of SARS RNA in effluents from PD patients with SARS infection.[@bib3]

The opposite results for both observations argue for performing a SARS-CoV-2 culture to confirm PD effluent contagiousness before imposing specific procedures in PD patients.
